Holen Sie sich die Stockscreener-App
20.49
3.28%
0.65
Vorhandelsmarkt:
20.42
-0.07
-0.34%
Schlusskurs vom Vortag:
$19.84
Offen:
$19.84
24-Stunden-Volumen:
666.22K
Relative Volume:
1.46
Marktkapitalisierung:
$910.84M
Einnahmen:
$10.32M
Nettoeinkommen (Verlust:
$-89.93M
KGV:
-8.5148
EPS:
-2.4064
Netto-Cashflow:
$-88.63M
1W Leistung:
+29.68%
1M Leistung:
+16.02%
6M Leistung:
+63.79%
1J Leistung:
+367.81%
1-Tages-Spanne:
$19.29
$21.26
1-Wochen-Bereich:
$15.13
$21.26
52-Wochen-Spanne:
$4.065
$24.00
Bioage Labs Inc Stock (BIOA) Company Profile
Firmenname
Bioage Labs Inc
Sektor
Telefon
510-806-1445
Adresse
5885 HOLLIS STREET, EMERYVILLE
Compare BIOA vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
20.49 | 881.94M | 10.32M | -89.93M | -88.63M | -2.4064 |
TAK
Takeda Pharmaceutical Co Adr
|
15.66 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.09 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.91 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
79.33 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
548.27 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-27 | Eingeleitet | Needham | Buy |
| 2026-02-25 | Eingeleitet | Oppenheimer | Outperform |
| 2026-02-18 | Hochstufung | Jefferies | Hold → Buy |
| 2026-01-27 | Eingeleitet | Piper Sandler | Overweight |
| 2025-12-05 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2025-10-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-02-28 | Eingeleitet | William Blair | Mkt Perform |
| 2024-12-10 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2024-12-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-10-21 | Eingeleitet | Citigroup | Buy |
| 2024-10-21 | Eingeleitet | Jefferies | Buy |
| 2024-10-21 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Bioage Labs Inc Aktie (BIOA) Neueste Nachrichten
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Beha - GuruFocus
BIOA News | BIOAGE LABS INC (NASDAQ:BIOA) - ChartMill
BioAge Labs (BIOA) director receives 22,000 stock options at $15.48 strike - Stock Titan
Director at BioAge Labs (BIOA) receives grant of 22,000 stock options - Stock Titan
BioAge Labs (BIOA) director James Healy receives 22,000 stock options at $15.48 - Stock Titan
BioAge Labs (BIOA) director receives grant of 22,000 stock options at $15.48 strike - Stock Titan
BioAge Labs (BIOA) director granted 22,000 stock options at $15.48 strike - Stock Titan
BioAge Labs (BIOA) director awarded 22,000 stock options at $15.48 - Stock Titan
BioAge Labs (NASDAQ: BIOA) shareholders elect directors and ratify KPMG at 2026 meeting - Stock Titan
BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securi - GuruFocus
BioAge Labs eyes key BGE-102 readouts in heart risk and diabetic eye disease - MSN
BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease - MarketBeat
BIOA Technical Analysis & Stock Price Forecast - Intellectia AI
BIOA: BGE-102 advances as a differentiated NLRP3 inhibitor with pivotal data expected by year-end - TradingView
BioAge Labs stock gains after positive early data and pipeline plans - MSN
BioAge Labs, Inc.Common Stock (NQ: BIOA - FinancialContent
BIOA Initiated by Roth Capital -- Price Target Set at $36.00 - GuruFocus
Roth Capital Partners Initiates BioAge Labs at Buy With $36 Price Target - marketscreener.com
Roth MKM Initiates BioAge Labs(BIOA.US) With Buy Rating, Announces Target Price $36 - Moomoo
Roth/MKM initiates BioAge Labs stock coverage with buy rating - Investing.com
Roth/MKM initiates BioAge Labs stock coverage with buy rating By Investing.com - Investing.com India
BIOA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
BioAge Labs to Present at Upcoming Investor Conferences - GlobeNewswire
BioAge executives to speak at Jefferies and Goldman healthcare forums - Stock Titan
Is BioAge Labs, Inc. (BIOA) a Top Longevity Biotech Stock to Watch After New Analyst Coverage? - Insider Monkey
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets - Benzinga
Shareholders that lost money on BioAge Labs, Inc.(BIOA) should c - GuruFocus
Khosla affiliates hold 1.8M shares in BioAge Labs (NASDAQ: BIOA), 4.0% stake - Stock Titan
Cormorant Asset Management reports 6.51% stake in BioAge Labs (BIOA) - Stock Titan
BioAge Labs, Inc. joins Amgen and Novo Nordisk to outline future obesity drug innovation at Fierce Biotech Week - Traders Union
Number of shareholders of BioAge Labs, Inc. – NASDAQ:BIOA - TradingView
BioAge Labs : BIOA - 24/7 Wall St.
Inside the cell-based Klotho therapy aiming to restore a longevity protein - Stock Titan
BioAge CEO has big plans for 'multi-disease impact' of NLRP3 drug across cardio, ocular and CNS - Fierce Biotech
BTIG initiates coverage of BioAge Labs (BIOA) with buy recommendation - MSN
BTIG Initiates BioAge Labs(BIOA.US) With Buy Rating, Announces Target Price $40 - Moomoo
BioAge Labs, Inc (BIOA) Stock News & Articles - 24/7 Wall St.
Earnings Update: Here's Why Analysts Just Lifted Their BioAge Labs, Inc. (NASDAQ:BIOA) Price Target To US$53.33 - Yahoo Finance
BTIG Initiates BioAge Labs at Buy With $40 Price Target - marketscreener.com
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Lexeo Therapeutics, Inc. (LXEO) - The Globe and Mail
Earnings Beat: BioAge Labs, Inc. (NASDAQ:BIOA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - simplywall.st
TradingKey - TradingKey
BioAge Labs: Analyst Reiterates Buy on Best-in-Class Potential of Lead NLRP3 Inhibitor BGE-102 After Encouraging Phase 1/2 Data - TipRanks
Needham Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $50 - Moomoo
BioAge Labs Releases Q1 2026 Financial Results - AlphaStreet
BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials - Barchart.com
BioAge Labs 1Q Research and Development Expenses Approximately $20.4M >BIOA - Moomoo
BioAge Labs, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
BioAge Labs 1Q Loss/Shr 52c >BIOA - Moomoo
BioAge Labs Q1 Loss Widens, Collaboration Revenue Rises - marketscreener.com
BioAge Labs Reports Positive Phase 1 Results for BGE-102 and Plans Upcoming Clinical Trials in Cardiovascular Risk and Diabetic Macular Edema - Quiver Quantitative
Finanzdaten der Bioage Labs Inc-Aktie (BIOA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Bioage Labs Inc-Aktie (BIOA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| RUBIN PAUL D | Chief Medical Officer |
Apr 01 '26 |
Option Exercise |
5.05 |
8,820 |
44,572 |
8,820 |
| RUBIN PAUL D | Chief Medical Officer |
Apr 01 '26 |
Sale |
17.81 |
8,820 |
157,084 |
0 |
2.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):